GSK plc (LSE/NYSE) has confirmed it has reached a confidential settlement with Boyd/Steenvoord, resolving the case filed in California state court.
The case, which was set to begin trial on 2 April 2024, will be dismissed. The settlement reflects the Company’s desire to avoid the distraction related to protracted litigation in this case.
GSK does not admit any liability in this settlement and will continue to vigorously defend itself based on the facts and the science in all other Zantac cases.
You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.
